AHR and Increased total eosinophil count: Compared to PBO, mepolizumab did not significantly modulate the AHR to His before and after allergen challenges, therefore the authors of the study suggested that blood and sputum eosinophilia might not represent the prerequisite for AHR in relation to allergen exposure and that several other cell types might be involved in these responses [39].